On March 29, 2022, GeneTether Therapeutics Inc. (CSE: GTTX) ("GeneTether" or the "Company"), an innovative genetic medicines company, completed an initial public offering (the "IPO") of units of the Company and a concurrent non-brokered private placement (together with the IPO, the "Public Offering"). Pursuant to the Public Offering, the Company issued 7,500,000 units at a price of C$0.60 per unit for aggregate gross proceeds of C$4,500,000. Research Capital Corporation acted as the sole agent and bookrunner for the IPO.
Fasken advised Research Capital Corporation with a team led by John Sabetti and including Onyi Ubah, Taylor West (Corporate Finance & Securities), Mitchell Thaw (Tax) and Armand Benitah (Intellectual Property).
Jurisdiction
- Ontario
